Pentagon’s Testosterone Screening Program—What Soldiers And Families Need To Know

The Pentagon will begin screening all active-duty troops over age 30 for low testosterone, a policy shift that affects hundreds of thousands of service members and their families. The move, announced in mid-July 2026, is designed to improve force readiness and address a growing health concern among aging military personnel.

Dr. Jesse Pines, a physician and researcher at the Uniformed Services University, explains that the Pentagon's new testosterone screening policy will test troops over 30 for clinically low testosterone levels, offering therapy to those who qualify. The policy applies to all active-duty soldiers, sailors, airmen, and Marines in that age bracket, though reservists and National Guard members may be included in future phases.

Testosterone levels naturally decline with age, but low testosterone—defined as below 300 ng/dL—can cause fatigue, muscle loss, depression, and reduced bone density. For soldiers, these symptoms can impair physical performance, decision-making, and combat readiness. The Pentagon has been studying the issue for years; a 2022 RAND report estimated that up to 15% of male troops over 30 may have clinically low testosterone. The new policy follows similar screening initiatives in the UK and Australian militaries.

Under the program, troops will provide a fasting morning blood test, with confirmatory testing if initial levels are borderline. Those diagnosed with hypogonadism—testosterone deficiency caused by testicular or pituitary dysfunction—can receive testosterone replacement therapy (TRT) through military health facilities. TRT is typically administered via gels, injections, or pellets. The policy explicitly excludes soldiers seeking testosterone solely for performance enhancement or bodybuilding. Dr. Pines emphasizes that TRT is not anabolic steroid abuse; it is a legitimate medical treatment when prescribed appropriately.

Critics worry about over-diagnosis and long-term risks of TRT, which include increased red blood cell count (polycythemia), sleep apnea exacerbation, and potential cardiovascular effects. A 2023 JAMA study found no increase in heart attacks among men receiving properly monitored TRT, but risks remain for those with underlying conditions. The Pentagon plans to require cardiovascular screening before starting therapy and regular blood monitoring.

The broader implications are significant: the policy could reshape military healthcare spending, reduce disability discharges related to fatigue and mental health, and set a precedent for other large employers. It also raises questions about gender equity—female troops are not included in the screening, though they can seek evaluation for hypogonadism through existing channels. Military family members may also benefit from improved awareness of low testosterone as a treatable condition.

Implementation begins in October 2026, with full rollout expected by early 2027. The Defense Health Agency will track outcomes and publish annual reports. Service members and families should watch for communication from their unit medical teams. For now, the message from experts is clear: the Pentagon testosterone screening policy is a data-driven move to tackle a hidden health problem, but it requires careful execution to avoid unintended harm.